I
n primary aldosteronism (PA), autonomous production of the salt-retaining hormone aldosterone leads to hypertension, often associated with hypokalemia (due to the kaliuretic action of aldosterone) (1) . PA was once believed to be rare and not worth looking for in the absence of hypokalemia (2) . However, the use of the plasma aldosterone/renin ratio (ARR) to screen for PA and its application among patients with both hypokalemic and normokalemic hypertension have revealed PA to be much more common than previously suspected, possibly accounting for up to 5% to 13% of cases of hypertension, and to be the most common specifically treatable and potentially curable form of secondary hypertension (3) (4) (5) (6) (7) (8) .
Although the ARR is considered the most reliable means of screening for PA, factors that affect secretion of renin and/or aldosterone can affect the ARR and lead to false-positive or false-negative results. These include antihypertensive agents (such as b-adrenoceptor blockers and a-methyl-dopa, which have the potential to cause false-positive results, and diuretics, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers, which can cause false-negative results) (9-13), antidepressants of the selective serotonin reuptake inhibitor class (which can lower the ARR) (14) , plasma potassium concentrations (15, 16) , dietary sodium intake (15, 16) , renal impairment (17) , and some physiologic factors (such as posture and time of day) (18, 19) .
Both exogenous estrogens and progestins (synthetic progesterones) can affect the components of the reninangiotensin-aldosterone system (RAAS) and therefore may alter the ARR. Oral estrogen administration stimulates production of renin substrate (20) , leading to decreases in direct renin concentration (DRC) (21) . Because of these opposing actions on substrate and enzyme, plasma renin activity (PRA), which measures the generation of the enzyme product angiotensin I, usually rises only minimally or not at all (21) . Although some progestins activate the RAAS in response to natriuresis induced by their antagonistic action at the mineralocorticoid receptor (22) , others have no effect or even inhibit the system (23, 24) . Consequently, the effects of progestins on RAAS components (and, importantly, on the ARR) could vary depending on the type of synthetic compound and on whether the progestins are used alone or in combination with estrogen.
We have previously reported that the combined oral contraceptive containing ethinylestradiol and drospirenone (a synthetic progesterone structurally related to spironolactone) raises the ARR and is associated with false-positive ARR levels in normotensive premenopausal women, but only when DRC, and not PRA, was used to calculate the ARR; in contrast, the subdermal implantation of etonogestrel (an active metabolite of desogestrel, a progestin derived from testosterone) had no effect (25) . We also found changing hormone levels during the normal menstrual cycle to be associated with differing effects on PRA and DRC, and hence on ARR, with the likelihood of false-positive ratios again being much greater with DRC than with PRA (26) .
Aldosterone is most commonly measured by immunoassay methods in clinical laboratories. However, concerns about the accuracy of these techniques have been raised (27, 28) , prompting us (and others) to develop an accurate high-performance liquid chromatographytandem mass spectrometry (HPLC-MS/MS) method (29) .
To our knowledge, there are no reported studies evaluating the effects of hormonal replacement therapy (HRT) on the ARR. In the current study, we evaluated the effect of combined HRT (conjugated estrogens 0.625 mg and medroxyprogesterone 2.5 mg daily) on the ARR, calculated by using both DRC and PRA, and using HPLC-MS/MS to measure plasma aldosterone (29) .
Materials and Methods

Participants
This study was performed with the approval of Princess Alexandra Hospital and University of Queensland Human Ethics Review Committees. Informed written consent was obtained from 20 healthy women who met the following inclusion criteria: consenting; healthy; postmenopausal; lacking evidence of renal, liver, or cardiovascular disease; not hypertensive; and not receiving any medications within the previous 2 months. Because of these strict criteria, we needed 2 years to recruit 20 patients who were about to begin receiving oral HRT (conjugated estrogens 0.625 mg and medroxyprogesterone 2.5 mg daily) by their treating physicians according to currently accepted treatment indications and guidelines. Patients were instructed to maintain their usual sodium intake during the study, and adherence was assessed by measuring urinary sodium excretion at each visit. Participants were excluded if history at follow-up visits revealed exposure to treatment with other medications, such as analgesics, antibiotics, and preparations available for supposed coryza or influenza. Other participants withdrew for personal reasons, leaving 15 women with a mean age (6 standard deviation) of 55 6 4 years who completed the study.
Sampling
Blood samples were collected at baseline and at 2 and 6 weeks after commencement of HRT. Samples were collected for measurement of plasma aldosterone, DRC, PRA, cortisol, sodium, potassium, and creatinine and serum estradiol, progesterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) between 9 and 10 AM after the participants had been seated for 5 to 15 minutes. Blood samples were centrifuged immediately at 2500 rpm for 10 minutes. Plasma was separated and snap frozen in dry ice and stored at 220°C pending assay. Blood pressure and heart rate were recorded during each visit. The mean of two readings was recorded after sitting for 10 to 15 minutes. Spot morning urine samples were also collected on the same day to measure urinary sodium, potassium, creatinine, cortisol, and aldosterone.
Analytic methods
Plasma aldosterone and cortisol were measured by HPLC-MS/MS, using a method recently developed in our laboratory (29) . For aldosterone, the interassay coefficients of variation were 5.0% at 139 pmol/L and 2.7% at 1110 pmol/L; the intraassay coefficients of variation were 6.3% at 139 pmol/L and 1.5% at 1110 pmol/L. For cortisol, the interassay coefficients of variation were 3.7% at 56 ng/mL and 1.8% at 462 ng/mL; the intra-assay coefficients of variation were 2.1% at 55 ng/mL and 1.6% at 472 ng/mL. DRC was assayed by chemiluminescent immunoassay (Liaison; DiaSorin, Saluggia, Italy). For DRC, the interassay coefficient of variations were 7.4% at 26 mU/L and 6.0% at 106 mU/L; the intra-assay coefficients of variation were 3.7%, 2.8%, 2.0%, and 1.2% at 15, 33, 82, and 258 mU/L, respectively. PRA was assayed by GammaCoat radioimmunoassay (DiaSorin, USA). For PRA, the interassay coefficients of variation were 10.0% at 1.6 ng/mL/h, 7.6% at 10.7 ng/mL/h, and 9.4% at 17.9 ng/mL/h; the intra-assay coefficients of variation were 5.6% at 1.6 ng/mL/h, 4.6% at 6.2 ng/mL/h, and 6.8% at 15.2 ng/mL/h. LH, FSH, estradiol, and progesterone were measured by immunoassay (Abbott Architect; Abbott Diagnostics, Sydney, Australia). Urinary cortisol was measured by HPLC and urinary aldosterone by radioimmunoassay (Siemens DPC, Washington, DC).
Statistical analysis
SPSS 24 for Windows (IBM, Chicago, IL) was used to analyze the data. Because data were not normally distributed, group data are presented as median (range). Nonparametric testing (Friedman test) was used for multiple comparisons. Pairwise comparisons were performed by using the Wilcoxon test. A P value ,0.05 was considered to indicate a statistically significant difference.
Results
The results of multiple comparisons of biochemical and hemodynamic parameters between the three collection time points in women using combined HRT are shown in Table 1 . Aldosterone, PRA, DRC, ARR calculated by using DRC, cortisol, FSH, LH, estrogen, and progesterone varied significantly during the study period. There were no significant changes in the levels of ARR calculated by PRA, plasma sodium, potassium, or creatinine and blood pressure and heart rate.
On the basis of the P value of the Friedman test in Table 1 , pairwise comparisons were performed only for parameters showing statistically significant changes and, in addition, for ARR calculated by using PRA. Results of pairwise (Wilcoxon) comparisons of measured parameters between each of the three collection time points are shown in Fig. 1 .
Compared with levels at baseline, 6-week concentrations of aldosterone, PRA, ARR calculated by DRC, and cortisol were significantly (P , 0.01) higher. Importantly, in three women, aldosterone/DRC ARR values exceeded the upper limit of the normal range (70) 6 weeks after commencing the treatment. DRC, FSH, and LH concentrations were lower (P , 0.01), whereas the ARR calculated by PRA did not change significantly. Estrogen (P , 0.001) and progesterone (P , 0.05) were significantly higher at 6 weeks, as expected.
Compared with baseline, 2-week concentrations were significantly (P , 0.001) higher for median (range) aldosterone [baseline, 150 (85 to 600) vs. LH concentration was significantly (P , 0.0.05) lower at 2 weeks. FSH tended to be lower, but the difference did not reach statistical significance (P = 0.08). There were no significant changes in DRC, ARR calculated by PRA, or cortisol concentrations.
Median aldosterone concentrations were higher at 6 weeks than at 2 weeks [6 weeks, 434 (200 to 1200) vs. . FSH and LH concentrations were also lower at 6 weeks (P , 0.01), whereas the ARR calculated by PRA did not change significantly.
Results of measured urinary parameters (corrected for creatinine) are presented in Table 2 . There were no significant differences between levels at baseline and those after 2 or 6 weeks of treatment of urinary potassium, sodium, and aldosterone or cortisol levels.
Discussion
We found statistically significant elevation of ARR using DRC but not PRA after commencement of the combined oral HRT preparation (conjugated estrogens 0.625 mg and medroxyprogesterone 2.5 mg daily). In three women, aldosterone/DRC ARR values exceeded the upper limit of the normal range after 6 weeks of treatment. These findings raise the possibility that use of PRA may be preferable to DRC in screening women for PA by ARR measurement without ceasing oral HRT agents. Alternatively, if PRA is not available, consideration might be given for repeating the ARR several weeks after withdrawing HRT (if feasible) in women who test positive by using DRC.
The effect of combined HRT on the ARR seen in this study could be explained as follows: Raised total estrogen increases plasma angiotensinogen (a renin substrate) by enhancing gene transcription and production by the liver (20) ; the resultant rise in angiotensin II levels [the rate of formation of which has previously been shown to be at least partly dependent on renin substrate concentration (30) ] chronically inhibits renal renin secretion by a negative feedback mechanism (21) , which leads to a fall in peripheral blood DRC (so the ARR calculated by DRC increases), counterbalancing the increase in concentration of renin substrate. Progesterone has antagonist activity at the mineralocorticoid receptor, thereby promoting natriuresis (31) . As a compensatory mechanism, PRA, plasma angiotensin II, and aldosterone increase (21) . Hence, because both aldosterone and PRA rose, the ARR calculated by using PRA did not change significantly. Interestingly, as we have previously reported for a combined oral contraceptive agent (25) , cortisol concentrations increased after initiation of HRT. Because cortisol in both studies was measured as total, rather than free, cortisol, a likely explanation for the higher levels would be increased production of cortisol-binding globulin by estrogen (32, 33) .
A false-positive result on an ARR screening test for PA (renin measured by DRC) has previously been reported in a normotensive woman taking a combined oral contraceptive (containing 3.0 mg of drospirenone and 30 mg of ethinylestradiol) (34) . The ratio calculated by using PRA was not studied. Similarly, an oral contraceptive pill containing gestodene 0.075 mg and estradiol 0.02 mg elevated the ARR calculated by DRC above the cutoff for PA (35) . Again, these results were not compared with the ratio calculated by PRA. As well, we have reported that an oral contraceptive pill containing ethinylestradiol plus drospirenone elevated the ARR calculated by DRC, but not by PRA, above the cutoff for PA (25) .
Limitations of this study include that only normotensive, and not hypertensive, participants were studied. However, renin measured as DRC in this study was reduced and aldosterone increased in women using HRT, and ARR (measured by using DRC) was elevated above the normal range after 6 weeks of treatment in three of them, providing proof in principle that HRT can lead to false-positive results. These findings justify the need to now study the hypertensive population in a similar way. The current study would have been enhanced by including patients taking other commonly used HRT preparations. However, the number of patients in whom the treating physicians involved in this study initiated other agents was not sufficient to permit meaningful statistical analysis; this remains another area worthy of future exploration.
In conclusion, using DRC to calculate ARR in oral HRT users appears to be associated with a higher risk for false-positive results, and consideration should be given to repeating the ARR after a period of HRT withdrawal if the ARR is positive under those circumstances. Alternatively, calculating the ratio using PRA (where available) in such patients would be preferable. 
